Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A.

Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83. doi: 10.1158/1940-6207.CAPR-10-0186. Epub 2010 Sep 1.

2.

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.

Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A.

Mol Carcinog. 2010 Jul;49(7):662-71. doi: 10.1002/mc.20637.

PMID:
20564343
3.

Colon epithelial proliferation and carcinogenesis in diet-induced obesity.

Takahashi H, Hosono K, Endo H, Nakajima A.

J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:41-7. doi: 10.1111/jgh.12240. Review.

PMID:
24251703
4.

Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.

Hurlstone DP, Karajeh M, Sanders DS, Drew SK, Cross SS.

Am J Gastroenterol. 2005 Jun;100(6):1283-9.

PMID:
15929758
5.

Calcium and colorectal epithelial cell proliferation: a preliminary randomized, double-blinded, placebo-controlled clinical trial.

Bostick RM, Potter JD, Fosdick L, Grambsch P, Lampe JW, Wood JR, Louis TA, Ganz R, Grandits G.

J Natl Cancer Inst. 1993 Jan 20;85(2):132-41.

PMID:
8418302
6.

Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence.

Uchiyama T, Takahashi H, Endo H, Kato S, Sakai E, Hosono K, Yoneda M, Inamori M, Hippo Y, Nakagama H, Nakajima A.

Dig Endosc. 2012 Sep;24(5):353-7. doi: 10.1111/j.1443-1661.2012.01289.x. Epub 2012 Apr 2.

PMID:
22925289
7.

Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.

Higurashi T, Hosono K, Endo H, Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E, Ohkubo H, Sakai E, Maeda S, Morita S, Natsumeda Y, Nagase H, Nakajima A.

BMC Cancer. 2012 Sep 19;12:413. doi: 10.1186/1471-2407-12-413.

8.

Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.

Sakai E, Takahashi H, Kato S, Uchiyama T, Hosono K, Endo H, Maeda S, Yoneda M, Taguri M, Nakajima A.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1918-24. doi: 10.1158/1055-9965.EPI-11-0104. Epub 2011 Jul 12.

9.

Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.

Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, Sakai E, Uchiyama T, Hata Y, Fujisawa N, Uchiyama S, Ezuka A, Nagase H, Kessoku T, Matsuhashi N, Yamanaka S, Inayama Y, Morita S, Nakajima A.

BMC Cancer. 2012 Mar 26;12:118. doi: 10.1186/1471-2407-12-118.

10.

Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.

11.

Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial.

Bostick RM, Fosdick L, Wood JR, Grambsch P, Grandits GA, Lillemoe TJ, Louis TA, Potter JD.

J Natl Cancer Inst. 1995 Sep 6;87(17):1307-15.

PMID:
7658483
12.

Chemoprevention of colorectal cancer.

Niitsu Y, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa T, Takahashi M, Matsunaga T, Kato J.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S40-3. Review.

PMID:
15309513
13.

Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.

Anderson JC, Swede H, Rustagi T, Protiva P, Pleau D, Brenner BM, Rajan TV, Heinen CD, Levine JB, Rosenberg DW.

Cancer Causes Control. 2012 Feb;23(2):355-61. doi: 10.1007/s10552-011-9884-7. Epub 2011 Dec 21.

PMID:
22187142
14.

Aberrant crypt foci: endoscopic assessment and cell kinetics characterization.

Figueiredo P, Donato M, Urbano M, Goulão H, Gouveia H, Sofia C, Leitão M, Freitas D.

Int J Colorectal Dis. 2009 Apr;24(4):441-50. doi: 10.1007/s00384-008-0576-z. Epub 2008 Sep 4.

PMID:
18769883
15.

Effect of vitamin A, C, and E supplementation on rectal cell proliferation in patients with colorectal adenomas.

Paganelli GM, Biasco G, Brandi G, Santucci R, Gizzi G, Villani V, Cianci M, Miglioli M, Barbara L.

J Natl Cancer Inst. 1992 Jan 1;84(1):47-51.

PMID:
1738173
16.

Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance.

Zhao X, Li Y, Chen M, Chen Y, Dai Y, Wang Y, Xie H.

Eur J Cancer Prev. 2015 Jan;24(1):27-36. doi: 10.1097/CEJ.0000000000000078.

PMID:
25162967
17.

Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.

Ohkubo H, Takahashi H, Yamada E, Sakai E, Higurashi T, Uchiyama T, Hosono K, Endo H, Taguri M, Nakajima A.

Oncol Rep. 2012 May;27(5):1475-80. doi: 10.3892/or.2012.1631. Epub 2012 Jan 12.

PMID:
22246586
18.

Histomorphology of aberrant crypt foci in colorectal carcinoma.

Norlida AO, Phang KS.

Malays J Pathol. 2010 Dec;32(2):111-6.

19.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
20.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124

Supplemental Content

Support Center